Background. This study investigates whether dose modifications for adverse hematologic effects or the use of hematopoietic growth factors influenced the outcome of therapy for hepatitis C virus (HCV) infection in patients who were coinfected with HCV and human immunodeficiency virus (HIV) and who were participants in a randomized, controlled trial.
Chronic hepatitis C virus (HCV) infection is common among individuals infected with HIV. In the United
States, 15%-33% of people with HIV infection are coinfected with HCV [1] [2] [3] [4] , and up to 60% of people who acquired HIV infection via injection drug use have chronic HCV infection [4, 5] . As a result of patients' increased longevity with the emergence of combination antiretroviral therapy, complications of HCV-related disease are becoming increasingly more important causes of morbidity and mortality in HIV-HCV-coinfected individuals [1, 6, 7] . Individuals with HIV infection have a higher HCV load [8] [9] [10] [11] , more rapid progression of fibrosis and cirrhosis [11] [12] [13] , and a more rapid development of hepatocellular carcinoma [14] , leading to increased mortality, compared with patients with HCV infection alone. The risk of cirrhosis or decompensated liver disease in patients with HIV-HCV coinfection is estimated to be 3 times that in patients infected with HCV alone [15] .
The efficacy of IFN or pegylated IFN (plus ribavirin) as treatment for HCV infection has been established in HCV-monoinfected patients and those with HCV-HIV coinfection, with sustained virologic responses of 47%-66% [16] [17] [18] and 12%-44% [19] [20] [21] [22] , respectively. Response rates among patients infected with HCV geno-type 1 are significantly lower than among those with nongenotype 1 HCV infection. Hematologic toxicity may be more pronounced in HIV-infected individuals than in those without HIV infection, especially for patients with underlying hematologic disorders.
People with chronic HIV infection are at risk for multiple hematologic abnormalities [23] [24] [25] . Chronic HCV infection can lead to leukopenia, anemia, and thrombocytopenia resulting from splenic sequestration in patients with cirrhosis and portal hypertension, as well as to anemia resulting from chronic inflammation and autoimmune hemolytic anemia [26] . Use of antiretrovirals and prophylactic medications, opportunistic infections, and malignancies, also contribute to cytopenia in people with HIV-HCV coinfection.
Both IFN and, to a greater degree, pegylated IFN can lead to bone marrow suppression [17, 18, 28] . Ribavirin is associated with a dose-dependent hemolytic anemia. Although combination therapy with IFN and ribavirin can occasionally lead to severe neutropenia and thrombocytopenia, an increase in infectious complications has not been noted, and spontaneous bleeding is rare [26, 27] . However, these adverse effects commonly lead health care providers to reduce the dose or discontinue therapy, which may negatively impact the outcome of therapy [29] . To date, the effect of dose modifications for hematologic toxicity on outcomes of therapy for HCV infection in individuals coinfected with HIV has not yet been described.
In randomized, controlled trials comparing IFN plus ribavirin with pegylated IFN plus ribavirin for the treatment of HIV-HCV-coinfected individuals, withdrawal from therapy occurred in up to 39% of subjects (12%-17% for adverse events) [19] [20] [21] . The rate of dose modification for hematologic toxicities varies. Most trials report the percentage of patients who require dose modification for anemia in the range of 8%-15%, 3%-12% for anemia, and only 2%-5% for thrombocytopenia [19] [20] [21] .
The Adult AIDS Clinical Trials Group A5071 study was a prospective, phase II/III, open-label, randomized, controlled trial designed to compare the efficacy, safety, and tolerability of IFN-alfa-2a plus ribavirin versus pegylated IFN-alfa-2a plus ribavirin for chronic HCV infection as treatment for chronic HCV infection in individuals coinfected with HIV-1. As has previously been reported, adverse events led to premature withdrawal from treatment for 8 subjects in each arm (12% overall); all withdrawals occurred within the first 20 weeks of treatment. Grade 4 anemia occurred in 3 subjects and was managed with dose modifications. Of the subjects who developed grade 4 neutropenia, 2 discontinued treatment, and 4 underwent dose modifications, some of which involved the addition of a hematopoietic growth factor. Only 1 subject experienced grade 4 thrombocytopenia [22] .
Because of the concern that overlapping hematologic complications of HIV and HCV coinfection and toxicity associated with IFN-alfa-2a and ribavirin therapy may have affected treatment outcomes, this analysis was undertaken to examine the effect of hematologic toxicity on the treatment outcome in the Adult AIDS Clinical Trials Group A5071 study.
METHODS

Subjects.
Subject selection, study design, and statistical methods have been described elsewhere [22] . Subjects aged у18 years were eligible to participate if they had chronic HIV infection and chronic HCV infection (HCV RNA level, 1600 IU/ mL). The CD4 + T lymphocyte count was required to be 1100 cells/mm 3 for subjects who were receiving stable antiretroviral therapy and 1300 cells/mm 3 for those who were not receiving antiretroviral therapy. Entry criteria also specified that all subjects should have an absolute neutrophil count 11000 cells/ mm 3 , a hemoglobin concentration у10.5 g/dL, and a platelet count у70,000 platelets/mm 3 . Treatment interventions. Because the safety of HCV treatment in HIV-HCV-coinfected patients was not known, ribavirin treatment was started at a dosage of 600 mg/day. If the hemoglobin concentration remained у10.5 g/dL, the dosage was escalated to 800 mg/day by week 5 and then to 1000 mg/ day by week 9; treatment stopped for any new onset of a hemoglobin concentration р10.5 g/dL, unless the dosage was 1000 mg/day and the hemoglobin concentration was у9.5 g/ dL, in which case it was reduced to 600 mg/day. If the hemoglobin concentration improved to у10.5 g/dL at the next assessment of the hemoglobin concentration, ribavirin treatment was restarted at 600 mg/day. Hemoglobin measurements were repeated 2-4 weeks after any new or worsening anemia.
The starting dose of IFN-alfa-2a was 6 million U subcutaneously 3 times weekly for the first 12 weeks and 3 million U 3 times weekly for the remaining 36 weeks; pegylated IFN-alfa2a was started at 180 mg subcutaneously weekly. IFN-alfa-2a and pegylated IFN-alfa-2a doses were delayed and/or adjusted if the neutrophil count decreased to !1000 cells/mm 3 and if the platelet count decreased to !50,000 platelets/mm 3 ; use of the drug was stopped if the platelet count decreased to !20,000 platelets/mm 3 . Treatment was also discontinued for subjects who experienced severe depression with suicidal ideation or acute psychosis requiring hospitalization. Erythropoietin and granulocyte-colony-stimulating factor (G-CSF) were administered at the discretion of the individual investigators. Other reasons for dose modifications or discontinuations included other toxicities and subject nonadherence to treatment or were otherwise not specified.
Assessments. Evaluations of symptoms and hematologic parameters were performed on weeks 2 and 4, then every 4 weeks until week 24, and then every 6 weeks until week 48. Assessments for efficacy and safety were made at 24 weeks. Subjects with a virologic response, defined as a viral load of !60 IU/mL, continued to receive treatment; those without a virologic response at week 24 underwent liver biopsy. Patients with histologic response (defined as a reduced hepatic activity index [30] by у2 points, compared with the pretreatment liver biopsy value) continued to receive treatment; those who did not have a histologic response or who did not undergo liver biopsy stopped receipt of the study drugs. Statistical analysis. We used descriptive statistics to characterize the study population by treatment arm, by use of antiretroviral therapy, and among patients receiving antiretroviral therapy, by CD4 + T lymphocyte count. "Treatment modification" refers to any dose reduction or discontinuation. The x nonresponse as the percentage of planned dose at 24 weeks, whereas for subjects allowed to continue to receive treatment after week 24, the adherence percentage was computed with respect to the planned cumulative dose at 48 weeks. The Kaplan-Meier, log rank, and Lowess analyses were performed using the freeware package R (R Foundation for Statistical Computing); all other analyses were performed using SAS software, version 8.2 (SAS Institute).
RESULTS
Description of the Study Subject Population
A total of 134 subjects were randomized to receive ribavirin plus either IFN-alfa-2a or pegylated IFN-alfa-2a. One subject was excluded after randomization, resulting in 67 subjects in the IFN-alfa-2a group and 66 subjects in the pegylated IFNalfa-2a group. Baseline hematologic variables did not differ significantly by antiretroviral therapy group, CD4 + T lymphocyte count, or treatment group (table 1) . Additionally, there were no significant associations between baseline hematologic values and hepatic activity index score or HCV genotype (data not shown).
During the course of the study, there were minor changes in mean hemoglobin concentration, neutrophil count, and platelet count over time, the pattern of which did not differ significantly between treatment groups. Among subjects who had treatment modifications, there was no significant difference in mean levels for the hematologic variables among subgroups defined by the reason for dose modification or the initiation of hematopoietic growth factor (erythropoietin and/or G-CSF). There were mild decreases in the mean hemoglobin concentration and neutrophil count in the first weeks after randomization that stabilized and/or improved over time. The mean platelet count appears to have decreased mildly in the pegylated IFN-alfa-2a group but not in the IFN-alfa-2a group; however, the level remained within the normal reference range (figure 1). At baseline, no patient was using G-CSF, and 1 patient was using erythropoietin (a protocol violation). (table 4) . This difference began to become apparent within the first 12 weeks after randomization (figure 2). Reasons for treatment modifications did not vary significantly between the IFN-alfa-2a and pegylated IFN-alfa-2a groups (tables 2 and 3). Although neutropenia led to majority of reductions in the IFN-alfa-2a and pegylated IFN-alfa-2a doses, it did not lead to any discontinuations. Similarly, the majority of ribavirin dose reductions were associated with anemia, but only 1 patient discontinued ribavirin because of anemia.
There were no differences in the treatment interventions when comparisons were made between subjects who received versus patients who did not receive antiretroviral therapy, between recipients of antiretroviral therapy regimens that contained zidovudine versus recipients of regimens that did not, between a CD4 + T lymphocyte count р200 cells/mm 3 versus 1200 cells/mm 3 , by HCV genotype, or by hepatic activity index score (data not shown).
Initiation of growth factor use. During the course of the study, 6 subjects in the IFN-alfa-2a group and 13 in the pegylated IFN-alfa-2a group used erythropoietin ( ); 10 in P p .08 the IFN-alfa-2a group and 23 in the pegylated IFN-alfa-2a group used G-CSF ( ). The mean total drug dose de-P p .008 livered did not differ between subjects who received versus those who did not receive growth factor support for IFN-alfa2a (1050 and 949 million IU of IFN-alfa-2a for patients who did and did not receive growth factor support, respectively; ) or for pegylated IFN-alfa-2a (40,358 and 42,498 mg P p .38 of pegylated IFN-alfa-2a, respectively;
). There was a P p .65 trend toward a higher mean total dose of delivered ribavirin in subjects who received growth factor support (234,247 vs. 201,416 mg of ribavirin;
). P p .067
Treatment Interventions as Predictors of Outcome
Multivariable logistic modeling was used to assess whether treatment assignment, compliance, or treatment interventions (dose reduction and discontinuation and initiation of growth factor support) affected the outcomes of HCV therapy. In the first model, which included type of interferon (pegylated IFNalfa-2a vs. IFN-alfa-2a) and adherence to IFN-alfa-2a and ribavirin treatment, randomization to the pegylated IFN-alfa-2a regimen versus IFN-alfa-2a regimen was associated with a more favorable outcome for both sustained virologic response (OR, 3.81; 95% CI, 1.45-10.01) and the combined end point of sustained virologic response or histologic response (OR, 2.79; 95% CI, 1.23-6.37). The finding of improved sustained virologic response rate in the group receiving pegylated IFN-alfa2a was reported previously [22] . Adherence with IFN treatment was also found to be associated with the combined end point of sustained virologic response or histologic response (OR, 1.44; 95% CI, 1.06-1.94). ), and/or ribavirin, by treatment n p 66 arm. P values were determined using the log rank test.
The second model includes dose modification for anemia, neutropenia, nonhematologic toxicity, initiation of hematopoietic growth factor (either erythropoietin or G-CSF), and other reason. Although no significant associations between treatment modifications (dose reduction or discontinuation), hematologic toxicity, and outcome were identified, modifications for nonhematologic toxicity (OR, 0.08; 95% CI, 0.01-0.67) and other, otherwise unspecified reasons (OR, 0.07; 95% CI, 0.01-0.59) were associated with a lower likelihood of sustained virologic response or histologic response.
The third model suggested that any dose modification was associated with a lower likelihood of sustained virologic response and/or histologic response (OR, 0.27; 95% CI, 0.11-0.69), independent of the type of IFN-alfa-2a and whether hematopoietic growth factor treatment was initiated. The initiation of erythropoietin or G-CSF therapy appears to be associated with an increase in the combined end point of sustained virologic response or histologic response (OR, 2.62; 95% CI, 1.04-6.58) (table 5) 
DISCUSSION
This analysis of data from a randomized, controlled trial comparing IFN-alfa-2a plus ribavirin with pegylated IFN-alfa-2a plus ribavirin for the treatment of HCV infection in subjects coinfected with HIV suggests that dose modification is associated with a lower response to therapy. Even though dose modification is more common in subjects treated with pegylated IFN-alfa-2a than with IFN-alfa-2a, compared with the other clinical features analyzed, treatment with pegylated IFNalfa-2a rather than IFN-alfa-2a was associated with a higher sustained virologic response and the combined outcome of sustained virologic response and/or histologic response-a finding that has been reported elsewhere [22] .
This study showed that dose reductions for any reason were associated with suboptimal outcomes, including those dose reductions made for nonhematologic reasons. We failed to show a significant association between dose reductions for hematologic toxicities and worse outcome, although this may have resulted from insufficient power, because such analysis was not part of the original clinical trial design. Not only was the number of participants relatively small, but the number of subjects requiring dose reductions for hematologic toxicity may have been lowered by the use of hematopoietic growth factors. It is Predictors of response to IFN-alfa-2a or pegylated IFN-alfa-2a NOTE. Multivariable logistic models assessing associations between potential predictors of outcomes and outcome (sustained virologic response, histologic response, and the combined end point) are shown. Predictors include treatment assignment (pegylated IFN-alfa-2a vs. IFN-alfa-2a), adherence to treatment (as a percentage of the drug dose received out of the maximum possible dose specified by the protocol), hematologic toxicity (anemia and neutropenia), nonhematologic toxicity, "other reason" not otherwise specified, and initiation of hematopoietic growth factor support (erythropoietin [EPO] or granulocyte-colony-stimulating factor [G-CSF]).
a Data with missing biopsy information were excluded. b Per 10%.
also possible that the use of growth factors by patients who had undergone dose reductions for hematologic toxicity allowed for subsequent dose escalation in these subjects, influencing this analysis towards the null hypothesis. There does appear to be an association between the use of hematopoietic growth factor and a higher combined end point of sustained virologic response and/or histologic response (table  5) . We did find a trend toward higher total ribavirin dose in subjects receiving growth factor support, compared with subjects who did not ( ), but there were no differences in P p .067 total IFN-alfa-2a or pegylated IFN-alfa-2a doses, regardless of whether hematopoietic growth factors were administered. Because the use of hematopoietic growth factors was not explicitly specified by the study protocol, there may have been variability in their use by study centers or individual investigators that was not necessarily based on the degree of hematologic toxicity, and they may have been used too late in the course of treatment. These factors could contribute to the lack of significant association between IFN-alfa-2a or pegylated IFN-alfa-2a doses and ribavirin doses and the use of erythropoietin or G-CSF.
Adherence to therapy (or the amount of antiviral therapy delivered) has been shown to be an important factor in outcome of therapy for HCV infection. Studies have shown that there is a higher sustained virologic response in persons who receive 180% of the intended drug dose, compared with those who do not [29, 31] .
A number of previous studies have shown that growth factors can be used to effectively manage hematologic toxicity due to anti-HCV therapy, although this approach has not been well studied in patients with HCV-HIV coinfection. A randomized, placebo-controlled trial of epoetin-alfa (40,000 U subcutaneously once per week) in HCV-infected patients who were treated with ribavirin plus either IFN-alfa-2a or pegylated IFNalfa-2a and who became anemic revealed that mean hemoglobin levels increased with epoetin-alfa treatment, and ribavirin doses were maintained in 88% of patients treated with epoetin-alfa, compared with 60% in the placebo arm. In an open-label phase of the study, both mean ribavirin dose and mean hemoglobin level increased when patients' regimens were switched to epoetin-alfa [32, 33] . A pilot study of darbepoetin-alfa (3 m/kg every 2 weeks) in HCV-infected patients who were treated with pegylated IFN-alfa-2a and ribavirin revealed an increase in hemoglobin levels and 92% maintenance of the ribavirin dose after 6 weeks [34, 35] . A cost-effectiveness analysis showed that the use of growth factors for treatment-induced anemia in HCV infection may lead to a quality-of-life-adjusted cost of $16,443-a number that is generally felt to be acceptable [36] .
A randomized trial of G-CSF (300 mg weekly) versus no G-CSF in 30 HCV-infected patients who were receiving IFN-alfa2a therapy demonstrated a nonsignificant trend toward higher sustained virologic response in the G-CSF group (53% vs. 40%; ) [37] . Another study of 39 patients treated with peg-P 1 .05 ylated IFN-alfa-2a and ribavirin showed a significant improvement in neutrophil counts in 89% of neutropenic patients who received G-CSF [35] . To date, to our knowledge, no studies have examined the use of pegylated G-CSF in HCV-monoinfected patients or the use of any myeloid growth factors for patients with HIV-HCV coinfection undergoing treatment.
Although the data from this analysis suggest that dose modification for hematologic toxicity may not affect outcome, the findings are limited by the fact that our clinical trial was not specifically designed to answer this question. Multivariate analysis revealed that any dose modification appeared to be associated with a worse outcome and that hematopoietic growth factor support was associated with an improved outcome, suggesting that there is a benefit with improved adherence to therapy and that hematopoietic growth factors may be used to facilitate maximal drug dosing. It is possible that earlier implementation of hematopoietic growth factor treatment may have prevented hematologic toxicities and reduced dose reductions for both hematologic and nonhematologic dose reasons, because reductions made on the basis of clinician and/ or subject decision could have been associated with symptoms of hematologic toxicity.
Because the rate of significant hematologic toxicity warranting dose modification is relatively uncommon during therapy-even for HCV-HIV-coinfected individuals-it will be important to study the outcomes in such individuals in larger clinical cohorts, to more accurately assess the effect of hematologic toxicities and use of growth factors on the outcome of HCV treatment. Because adherence to therapy is an important factor in optimal outcome of anti-HCV therapy, any dose reduction should be avoided. Until more definitive data are available, it makes sense to use hematopoietic growth factors to help prevent dose reductions.
